Rainbow Childrens Medicare Ltd Q4 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Published 5 Aug 2026 | Healthcare Services | Market Cap: ₹16.2K Cr
Rainbow Children's Medicare expects late teens to 20% revenue CAGR over the next 3 years, driven by a high-teens growth trajectory. Rainbow Children's Medicare expects revenue growth in the late teens to 20% range going forward.
From Rainbow Childrens Medicare Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Price
₹1,433
Market Cap
₹16.2K Cr
P/E Ratio
56.7
How does Rainbow Childrens Medicare Ltd rank in Healthcare Services?
Compare Rainbow Childrens Medicare Ltd against every Healthcare Services company this quarter on revenue, margins and earnings-call signals.
Rainbow Childrens Medicare Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹460 Cr, net profit ₹78 Cr.
Full financials →📊 Revenue & Sales Performance
- →Rainbow Children's Medicare expects late teens to 20% revenue CAGR over the next 3 years, driven by a high-teens growth trajectory.
- →OPD revenue growth is expected to mirror overall revenue growth, maintaining around 30% contribution.
- →ARPP (Average Revenue Per Patient) growth is forecasted around 5-6% annually, indicating underlying revenue efficiency.
- →Mature hospitals typically achieve 8-10% growth; new hospitals scale occupancy before increasing pricing and ARPOB.
- →Pediatric volumes experienced a 12% growth for the full year, with inpatient volumes up 10%. Deliveries grew 6%.
- →Expansion through new hospitals and bed additions (~250 beds planned) will further drive volume and revenue growth.
- →Business growth is expected despite Q4 seasonality; long-term resilience is being built via specialty additions and capacity expansions.
📈 Profitability & Margins
- →Rainbow Children's Medicare expects revenue growth in the late teens to 20% range going forward.
- →Operating EBITDA margins are targeted at a minimum of 25% (pre-Ind AS), with aspirations of reaching 26%-26.5% as capacity matures.
- →Margin pressure of 0.5%-1% may occur temporarily with bed additions but is expected to normalize with operational efficiencies.
- →Mature hospitals typically achieve 8%-10% growth, with the overall portfolio targeting mid-teens CAGR over 3-5 years.
- →EBITDA losses from newly opened hospitals (around ₹12-13 crores in FY25) are expected to neutralize by FY26.
- →Average Revenue Per Patient (ARPP) growth around 5%-6% is expected, supporting stable operating performance.
- →Profit After Tax (PAT) grew 11.9% in FY25; future EPS growth should align with high teens revenue and operating profit growth, assuming stable margins.
🏗️ Capital Expenditure Plans
- →The company plans capital expenditures of around INR 650 crores over the next 3 years, consistent with previous guidance.
- →Capex in the recent quarter was approximately INR 43.7 crores; full-year capex stood at INR 145.7 crores.
- →New bed capacity addition of about 250 beds is planned, including ~150 beds in Bangalore and ~100 beds in Rajahmundry.
- →The company expects to fund all planned capex from internal accruals and existing cash reserves (~INR 700 crores) without debt financing.
- →Strategic inorganic growth opportunities, particularly outside Hyderabad, are being actively evaluated, though inorganic expansion in Hyderabad is unlikely.
- →Focus remains on organic growth and integrating IVF services within existing hospital ecosystems.
💰 Fundraising & Capital Structure
- →The company currently has strong cash reserves of approximately ₹700 crores as of March 31, 2025.
- →They remain confident in their ability to complete all planned capital expenditures over the coming years solely through internal accruals without requiring any debt financing.
- →There is no mention of any immediate or near-term plans for new fundraising through either debt or equity.
- →The management emphasizes a preference for organic growth supported by cash flows rather than raising external funds.
- →No explicit discussions or guidance about future fundraising activities were disclosed in the call transcript.
📋 Order Book & Pipeline
Key Metrics
Frequently Asked Questions
What were Rainbow Childrens Medicare Ltd Q4 FY25 results?
Rainbow Children's Medicare expects late teens to 20% revenue CAGR over the next 3 years, driven by a high-teens growth trajectory. Rainbow Children's Medicare expects revenue growth in the late teens to 20% range going forward.
What is Rainbow Childrens Medicare Ltd share price analysis?
Rainbow Childrens Medicare Ltd currently shows a neutral. The stock trades at a P/E of 56.7 with a market cap of ₹16,236 Cr. Investors should review the full earnings analysis for detailed insights.
Is Rainbow Childrens Medicare Ltd planning capital expenditure?
The company plans capital expenditures of around INR 650 crores over the next 3 years, consistent with previous guidance.
Keep Rainbow Childrens Medicare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.